David Amsellem Recent News
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
Piper Jaffray Downgrades Allergan, Slashes Target To $238
Amsellem: Valeant Has No Floor
Valeant's Calls To Analysts 'Raise Disclosure Questions'
UPDATE: Piper Jaffray Upgrades Forest Laboratories, Previous Thesis is No Longer Tenable
UPDATE: Piper Jaffray Initiates Coverage on Discovery Laboratories on Emerging Respiratory Franchise at Breathtaking Value
UPDATE: Piper Jaffray Downgrades Santarus Following Salix Acquisition Announcement
UPDATE: Piper Jaffray Upgrades Endo Health Solutions as Paladin Transaction is a Game-Changer
UPDATE: Piper Jaffray Downgrades Pacira Pharmaceuticals Following 2Q13 Net Loss
UPDATE: Piper Jaffray Upgrades Questcor Pharmaceuticals Following Strong 2Q13 Report
UPDATE: Piper Jaffray Lowers PT on Allergan Following FDA Draft Guidance
UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue Gaining Traction
UPDATE: Piper Jaffray Initiates The Medicines Company at Overweight on Diverse Medical Portfolio
UPDATE: Piper Jaffray Raises PT on Actavis on Pro Forma Estimates
Salix Pharmaceuticals (SLXP) Gets Overweight From Piper Jaffray
Impax Weakness Overblown, Cash Still Flowing; Piper Jaffray (IPXL)
Piper Jaffray Reiterates Salix Pharmaceuticals (SLXP) Overweight Rating